Stock listing
Lang & Schwarz:899376 Lifecore Biomedical, Inc. Aktie
German listing (Lang & Schwarz) of Lifecore Biomedical, Inc. · home listing NASDAQ:LFCR
Follow Lifecore Biomedical, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:LFCR
$6.39 USD -0.01 (-0.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:LFCR
- Day range
- $6.37 – $6.39 USDNov 20, 2026
- Volume
- 218,736 sharesNov 20, 2026
- Market cap
- $242.2M USDAt the close on Nov 20, 2026 · price × 37.91M shares outstanding
- 52-week range
- $3.63 – $8.98 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.47M USDMedian day 229,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LFCR · Home | $6.39 USD | -0.01 (-0.2%) | 218,736 | $6.37 | $6.39 | $6.369 | $6.40 | Close on Nov 20, 2026 |
| Frankfurt:LDE | €5.65 EUR | -0.10 (-1.7%) | — | €5.65 | €5.65 | €5.65 | €5.75 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LFCR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.39 | -0.01 | -0.2% | $6.37 | $6.39 | $6.369 | 218,736 | |
| $6.40 | +0.01 | +0.2% | $6.40 | $6.405 | $6.39 | 147,540 | |
| $6.39 | -0.025 | -0.4% | $6.41 | $6.42 | $6.39 | 181,969 | |
| $6.415 | -0.005 | -0.1% | $6.41 | $6.42 | $6.40 | 65,923 | |
| $6.42 | +0.02 | +0.3% | $6.40 | $6.42 | $6.38 | 83,094 | |
| $6.40 | 0.00 | 0.0% | $6.38 | $6.40 | $6.38 | 108,889 | |
| $6.40 | +0.03 | +0.5% | $6.37 | $6.40 | $6.37 | 149,717 | |
| $6.37 | 0.00 | 0.0% | $6.37 | $6.385 | $6.37 | 369,580 | |
| $6.37 | +0.01 | +0.2% | $6.36 | $6.39 | $6.36 | 142,904 | |
| $6.36 | -0.04 | -0.6% | $6.38 | $6.39 | $6.36 | 780,492 | |
| $6.40 | -0.04 | -0.6% | $6.45 | $6.45 | $6.375 | 700,056 | |
| $6.44 | +0.02 | +0.3% | $6.44 | $6.45 | $6.41 | 270,724 | |
| $6.42 | +0.03 | +0.5% | $6.41 | $6.44 | $6.405 | 297,915 | |
| $6.39 | -0.01 | -0.2% | $6.40 | $6.42 | $6.375 | 483,332 | |
| $6.40 | -0.12 | -1.8% | $6.48 | $6.499 | $6.315 | 1,023,939 | |
| $6.52 | +0.01 | +0.2% | $6.52 | $6.52 | $6.47 | 240,905 | |
| $6.51 | +0.07 | +1.1% | $6.44 | $6.51 | $6.43 | 365,155 | |
| $6.44 | 0.00 | 0.0% | $6.36 | $6.44 | $6.36 | 441,609 | |
| $6.44 | +0.04 | +0.6% | $6.41 | $6.44 | $6.40 | 436,363 | |
| $6.40 | +0.03 | +0.5% | $6.36 | $6.40 | $6.36 | 224,000 | |
| $6.37 | 0.00 | 0.0% | $6.37 | $6.39 | $6.36 | 178,700 | |
| $6.37 | 0.00 | 0.0% | $6.40 | $6.40 | $6.36 | 270,400 | |
| $6.37 | -0.02 | -0.3% | $6.38 | $6.40 | $6.37 | 588,300 | |
| $6.39 | +0.01 | +0.2% | $6.38 | $6.42 | $6.38 | 229,900 | |
| $6.38 | -0.06 | -0.9% | $6.42 | $6.44 | $6.38 | 1,424,600 | |
| $6.44 | +0.02 | +0.3% | $6.44 | $6.48 | $6.42 | 233,400 | |
| $6.42 | 0.00 | 0.0% | $6.40 | $6.44 | $6.40 | 268,000 | |
| $6.42 | -0.02 | -0.3% | $6.46 | $6.46 | $6.40 | 590,600 | |
| $6.44 | -0.01 | -0.2% | $6.45 | $6.46 | $6.43 | 312,000 | |
| $6.45 | +0.02 | +0.3% | $6.43 | $6.46 | $6.42 | 387,100 | |
| $6.43 | -0.01 | -0.2% | $6.43 | $6.46 | $6.42 | 492,100 | |
| $6.44 | -0.01 | -0.2% | $6.45 | $6.48 | $6.43 | 1,720,300 | |
| $6.45 | -0.07 | -1.1% | $6.51 | $6.54 | $6.44 | 1,232,100 | |
| $6.52 | -0.02 | -0.3% | $6.54 | $6.57 | $6.51 | 840,600 | |
| $6.54 | +0.01 | +0.2% | $6.55 | $6.55 | $6.53 | 504,500 | |
| $6.53 | -0.05 | -0.8% | $6.57 | $6.58 | $6.53 | 707,000 | |
| $6.58 | -0.01 | -0.2% | $6.55 | $6.61 | $6.54 | 970,200 | |
| $6.59 | +0.07 | +1.1% | $6.53 | $6.61 | $6.51 | 685,300 | |
| $6.52 | +2.32 | +55.2% | $6.52 | $6.65 | $6.40 | 4,005,300 | |
| $4.20 | -0.09 | -2.1% | $4.27 | $4.39 | $4.12 | 70,500 | |
| $4.29 | -0.11 | -2.5% | $4.41 | $4.41 | $4.21 | 97,200 | |
| $4.40 | -0.10 | -2.2% | $4.45 | $4.49 | $4.39 | 205,200 | |
| $4.50 | +0.02 | +0.4% | $4.52 | $4.52 | $4.37 | 90,400 | |
| $4.48 | +0.02 | +0.4% | $4.48 | $4.51 | $4.22 | 170,700 | |
| $4.46 | 0.00 | 0.0% | $4.44 | $4.55 | $4.33 | 280,800 | |
| $4.46 | +0.30 | +7.2% | $4.22 | $4.48 | $4.16 | 144,700 | |
| $4.16 | +0.02 | +0.5% | $4.11 | $4.33 | $4.10 | 94,900 | |
| $4.14 | -0.11 | -2.6% | $4.21 | $4.23 | $4.13 | 76,100 | |
| $4.25 | +0.13 | +3.2% | $4.12 | $4.28 | $4.02 | 110,700 | |
| $4.12 | +0.03 | +0.7% | $4.14 | $4.19 | $4.06 | 159,500 | |
| $4.09 | 0.00 | 0.0% | $4.00 | $4.27 | $4.00 | 199,000 | |
| $4.09 | -0.22 | -5.1% | $4.29 | $4.31 | $4.03 | 264,800 | |
| $4.31 | -0.09 | -2.0% | $4.36 | $4.40 | $4.28 | 185,700 | |
| $4.40 | +0.05 | +1.1% | $4.35 | $4.60 | $4.29 | 277,400 | |
| $4.35 | -0.39 | -8.2% | $4.69 | $4.69 | $4.34 | 121,300 | |
| $4.74 | +0.35 | +8.0% | $4.42 | $4.80 | $4.42 | 235,900 | |
| $4.39 | -0.07 | -1.6% | $4.45 | $4.49 | $4.35 | 81,300 | |
| $4.46 | -0.08 | -1.8% | $4.50 | $4.61 | $4.45 | 88,000 | |
| $4.54 | 0.00 | 0.0% | $4.54 | $4.65 | $4.47 | 132,000 | |
| $4.54 | -0.11 | -2.4% | $4.64 | $4.70 | $4.53 | 122,300 | |
| $4.65 | +0.01 | +0.2% | $4.64 | $4.76 | $4.55 | 86,400 | |
| $4.64 | +0.09 | +2.0% | $4.55 | $4.83 | $4.55 | 113,413 | |
| $4.55 | +0.01 | +0.2% | $4.55 | $4.59 | $4.37 | 101,453 | |
| $4.54 | +0.02 | +0.4% | $4.58 | $4.70 | $4.50 | 90,600 | |
| $4.52 | +0.06 | +1.3% | $4.42 | $4.57 | $4.32 | 121,500 |
- Ticker
- Lang & Schwarz:899376
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
Latest earnings call · Aug 5, 2026
Lifecore Biomedical (NASDAQ:LFCR) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Sep 28, 2026
Merger or Acquisition (September 2026)
Merger or acquisition · 11 slides
Latest news
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
Nov 4, 2026
Closed $6.44 (+0.3%) on Nov 4, 2026
Lifecore Biomedical to Participate at Upcoming Industry Conferences
Oct 7, 2026
Closed $6.43 (-0.2%) on Oct 8, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners
Sep 29, 2026
Closed $6.59 (+1.1%) on Sep 29, 2026
Lifecore Biomedical to Participate at CPHI Global Conference
Sep 3, 2026
Closed $4.40 (+1.1%) on Sep 4, 2026
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
Sep 2, 2026
Closed $4.74 (+8.0%) on Sep 2, 2026
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
Aug 5, 2026
Closed $4.44 (+2.1%) on Aug 5, 2026
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026
Jul 29, 2026
Closed $4.36 (+0.9%) on Jul 30, 2026
Lifecore Biomedical Signs Three New Customer Agreements
Jul 28, 2026
Closed $4.39 (+1.2%) on Jul 28, 2026
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
Jun 15, 2026
Closed $5.49 (-2.7%) on Jun 15, 2026
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
Jun 2, 2026
Closed $5.45 (+12.4%) on Jun 2, 2026
Lifecore Biomedical, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 28 in the last 12 months · 84 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 19 calls with a replay · 19 with a transcript · latest Aug 5, 2026
- Decks
- 17 decks · latest Sep 28, 2026
Where Lifecore Biomedical, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LFCR · Home listing | NASDAQ | United States | USD |
| gettex:LDE | gettex | Germany | EUR |
| Lang & Schwarz:899376 · This page | Lang & Schwarz | Germany | EUR |
| LS Exchange:899376 | LS Exchange | Germany | EUR |
| BOATS:LFCR | BOATS | United States | USD |
| Frankfurt:LDE | Frankfurt | Germany | EUR |
| Dusseldorf:LDE | Dusseldorf | Germany | EUR |
| Stuttgart:LDE | Stuttgart | Germany | EUR |
| Tradegate:LDE | Tradegate | Germany | EUR |
Valuation
EV/sales 2.9× against a median of 4.0×: 5th lowest of 10 Diagnostics & research services companies shown. Statements: Year to May 31, 2026 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $380.1M USD
- P/E
- Loss
- EV/sales
- 2.9×
- EV/EBITDA
- 46.1×
- Price/book
- Negative equity
- Gross margin
- 31.4%
- Operating margin
- −1.0%
- Net margin
- −23.8%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.51
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lifecore Biomedical, Inc. · NASDAQ:LFCR | US$242.2M | US$380.1M | n/a | 2.9× | 46.1× | n/a | −23.8% | n/a | 0.51 |
| Eurobio-Scientific SA · EURONEXT:ALERS | US$291.7M | US$279.0M | 54.6× | 1.5× | 7.8× | 1.4× | 2.9% | 0.1× | n/a |
| Jinan High-tech Development Co., Ltd. Class A · SSE:600807 | US$281.5M | US$159.8M | n/a | 2.6× | n/a | 7.2× | −51.6% | 0.1× | n/a |
| Dirui Industrial Co., Ltd. Class A · SZSE:300396 | US$270.6M | US$206.0M | n/a | 1.4× | n/a | 1.2× | −18.0% | 0.1× | n/a |
| Nautilus Biotechnology, Inc. · NASDAQ:NAUT | US$270.0M | US$183.5M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.47 |
| Shanghai Hile Bio-technology Co Ltd Class A · SSE:603718 | US$256.2M | US$222.0M | n/a | 5.3× | n/a | 1.9× | −111.9% | 0.1× | n/a |
| Jiangsu Cowin Biotech Co., Ltd. Class A · SSE:688426 | US$250.1M | US$138.3M | n/a | 4.0× | n/a | 1.3× | −35.4% | 0.0× | n/a |
| OraSure Technologies, Inc. · NASDAQ:OSUR | US$238.9M | US$102.3M | n/a | 0.9× | n/a | 0.8× | −41.7% | 0.0× | 1.21 |
| Shanghai Rendu Biotechnology Co., Ltd. Class A · SSE:688193 | US$216.7M | US$100.3M | 64.7× | 4.2× | n/a | 1.6× | 13.9% | 0.0× | n/a |
| Median Technologies · EURONEXT:ALMDT | US$214.8M | US$176.5M | n/a | 6.9× | n/a | n/a | −145.8% | n/a | n/a |
| Tomocube, Inc. · KRX:475960 | US$208.3M | US$187.2M | n/a | 16.6× | n/a | 7.4× | −16.1% | 0.0× | n/a |
| Median of the others | US$253.1M | US$180.0M | 59.7× | 4.0× | 7.8× | 1.6× | −35.4% | 0.0× | 1.34 |
Forecasts
5 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.28 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.83 · 1 analyst
- Revenue, year to Dec 2026
- 120.4M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Paul Josephs | Chief Executive Officer |
| Ryan D. Lake | Chief Financial Officer |
| Tom Salus | Chief Legal and Administration Officer |
| Jackie Klecker | Executive Vice President, Quality and Development Services |
| Thomas Guldager | Sr. Vice President, Operations |
| Mark DaFonseca | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Paul Josephs | Chief Executive Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Lifecore Biomedical (NASDAQ:LFCR) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 8:00 AM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q1 2026 Earnings Call | Wed, May 06, 2026 · 8:00 AM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q4 2025 Earnings Call | Mon, Mar 16, 2026 · 8:30 AM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 4:30 PM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q4 2024 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q3 2024 Earnings Call | Thu, Apr 03, 2025 · 4:30 PM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q2 2024 Earnings Call | Thu, Jan 02, 2025 · 4:30 PM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q1 2024 Earnings Call | Fri, Oct 04, 2024 · 8:30 AM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q4 2023 Earnings Call | Thu, Aug 31, 2023 · 8:30 AM ET | Replay |
| Lifecore Biomedical (NASDAQ:LFCR) Q3 2023 Earnings Call | Thu, Jun 01, 2023 · 8:30 AM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| Landec Corporation (LNDC) Q1 2023 Earnings Call | Wed, Oct 05, 2022 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q4 2022 Earnings Call | Wed, Aug 10, 2022 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q3 2022 Earnings Call | Tue, Apr 05, 2022 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q2 2022 Earnings Call | Wed, Jan 05, 2022 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q1 2022 Earnings Call | Wed, Sep 29, 2021 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q4 2021 Earnings Call | Wed, Jul 28, 2021 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q3 2021 Earnings Call | Wed, Apr 07, 2021 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q2 2021 Earnings Call | Wed, Jan 06, 2021 · 5:00 PM ET | Replay |
| Landec Corporation (LNDC) Q1 2021 Earnings Call | Tue, Oct 06, 2020 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 4, 2026 · Before open | +0.3% |
| Q4 2026 | Aug 5, 2026 · Before open | +2.1% |
| Q3 2026 | Apr 7, 2026 · After close | +3.2% |
| Q2 2026 | Jan 1, 2026 | −5.4% |
| Q1 2026 | Nov 6, 2025 · After close | +3.5% |
| Q4 2025 | Aug 7, 2025 · After close | −6.7% |
| Q3 2025 | Apr 3, 2025 · After close | −22.3% |
| Q2 2025 | Jan 2, 2025 · After close | +14.4% |
| Q1 2025 | Oct 4, 2024 · Before open | +14.3% |
| Q4 2024 | Aug 26, 2024 · After close | −25.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | Dec 29, 2023 · Before open | +0.2% |
| Q1 2024 | Nov 14, 2023 · Before open | +6.7% |
| Q4 2023 | Aug 31, 2023 · Before open | −11.8% |
| Q3 2023 | Mar 16, 2023 · After close | −67.3% |
| Q2 2023 | Feb 27, 2023 · After close | +0.5% |
| Q1 2023 | Oct 6, 2022 · Before open | +0.1% |
| Q4 2022 | Aug 10, 2022 · After close | +2.6% |
| Q3 2022 | Apr 5, 2022 · After close | −6.0% |
| Q2 2022 | Jan 5, 2022 · After close | +1.0% |
| Q1 2022 | Sep 29, 2021 · After close | −10.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (September 2026) | Merger or acquisition | 11 slides | Sep 28, 2026 |
| Investor Presentation (August 2026) | Investor deck | 23 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 23 slides | May 6, 2026 |
| Transition period en Earnings Presentation | Earnings | 25 slides | Mar 16, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 20 slides | Mar 16, 2026 |
| FY2025 Earnings Presentation | Earnings | 33 slides | Nov 6, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 33 slides | Nov 6, 2025 |
| Jefferies Global Healthcare Conference 2025 | Conference | 22 slides | November 2025 |
| Investor Presentation (August 2025) | Investor deck | 33 slides | Aug 12, 2025 |
| Q3 FY2025 Earnings Presentation | Earnings | 26 slides | Apr 3, 2025 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2025) | Investor deck | 27 slides | Jan 2, 2025 |
| Investor Day (November 2024) | Investor day | 39 slides | Nov 21, 2024 |
| Investor Presentation (October 2024) | Investor deck | 22 slides | Oct 4, 2024 |
| Investor Presentation (April 2024) | Investor deck | 29 slides | Apr 1, 2024 |
| FY2023 Earnings Presentation | Earnings | 5 slides | Mar 20, 2024 |
| Landec Corp \ca\ — Investor Presentation (August 2022) | Investor deck | 24 slides | Aug 10, 2022 |
| Landec Corp \ca\ — Investor Presentation (January 2022) | Investor deck | 22 slides | Jan 10, 2022 |
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.5M | 128.9M | 128.3M | 103.3M | 111.3M | 100.9M | 160.1M | 557.6M | 524.2M | 469.8M |
| Cost of revenue | 88.9M | 88.6M | 86.4M | 75.3M | 72.2M | 61.9M | 120.7M | 476.6M | 445.9M | 390.6M |
| Gross profit | 40.6M | 40.3M | 41.9M | 28.0M | 39.1M | 38.9M | 39.4M | 81.0M | 78.3M | 79.2M |
| Research and development | 8.50M | 8.26M | 8.57M | 8.74M | 7.84M | 6.68M | 7.58M | 11.5M | 12.8M | 9.47M |
| Selling, general and administrative | 44.0M | 40.5M | 39.0M | 34.7M | 27.7M | 40.7M | 62.1M | 52.0M | 52.5M | |
| Operating income | -1.26M | -17.2M | -8.84M | -21.8M | -11.8M | -8.82M | -25.9M | 5.47M | 13.6M | 14.7M |
| Depreciation and amortization | 9.50M | 8.03M | 7.95M | 13.2M | 18.1M | 19.9M | 18.8M | 15.2M | 12.4M | 10.7M |
| EBITDA | 8.24M | -9.22M | -890.0K | -8.62M | 6.27M | 11.0M | -7.04M | 20.7M | 26.0M | 25.3M |
| Interest expense | 2.21M | 22.2M | 18.1M | 17.6M | 15.6M | 8.93M | 4.65M | 5.23M | 1.95M | 1.83M |
| Income before tax | -30.2M | -38.7M | 9.51M | -63.9M | -20.7M | -29.8M | -30.6M | 3.64M | 16.4M | 14.2M |
| Income tax | 577.7K | 43.0K | 183.0K | 308.0K | -5.21M | -6.35M | -8.77M | 1.52M | -9.36M | 4.04M |
| Net income | -30.8M | -38.7M | 12.0M | -99.6M | -116.7M | -32.3M | -38.2M | 411.0K | 24.8M | 10.6M |
| Earnings per share, basic | -0.82 | -1.27 | 0.39 | -3.32 | -3.97 | -1.10 | -1.31 | 0.01 | 0.90 | 0.39 |
| Earnings per share, diluted | -1.27 | 0.33 | -3.32 | -3.97 | -1.10 | -1.31 | 0.01 | 0.89 | 0.38 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.5M | 8.27M | 8.46M | 19.1M | 991.0K | 763.0K | 360.0K | 1.08M | 2.90M | 6.00M |
| Receivables | 33.8M | 43.7M | 31.2M | 29.0M | 38.3M | 31.6M | 76.2M | 69.6M | 53.9M | 45.9M |
| Inventory | 29.1M | 32.3M | 40.0M | 40.8M | 36.0M | 33.9M | 66.3M | 54.1M | 31.8M | 23.6M |
| Current assets | 82.3M | 85.7M | 81.0M | 93.9M | 116.7M | 145.3M | 157.1M | 133.0M | 97.1M | 81.3M |
| Property, plant and equipment | 129.0M | 149.2M | 134.4M | 118.7M | 107.1M | 192.3M | 200.0M | 159.6M | 133.2M | |
| Goodwill | 13.9M | 13.9M | 13.9M | 13.9M | 13.9M | 13.9M | 33.9M | 76.7M | 54.5M | 54.5M |
| Total assets | 232.2M | 239.3M | 254.0M | 253.5M | 274.7M | 501.9M | 293.5M | 519.1M | 404.7M | 358.6M |
| Accounts payable | 5.84M | 8.22M | 16.3M | 22.1M | 13.0M | 11.6M | 51.6M | 54.0M | 34.7M | 24.5M |
| Current liabilities | 23.6M | 30.2M | 38.9M | 39.3M | 176.6M | 101.9M | 164.4M | 137.1M | 88.4M | 51.5M |
| Long-term debt | 135.6M | 127.0M | 100.8M | 84.3M | 0 | 164.9M | 101.4M | 87.2M | 37.4M | 42.3M |
| Total debt | 142.6M | 130.4M | 124.7M | 84.8M | 98.2M | 164.9M | 112.9M | 97.0M | 42.3M | 47.2M |
| Total liabilities | 246.4M | 191.9M | 200.1M | 218.5M | 186.9M | 299.9M | 310.3M | 248.9M | 152.1M | 130.5M |
| Shareholders' equity | -14.2M | 1.34M | 11.3M | -4.23M | 87.8M | 201.9M | 229.8M | 270.1M | 252.6M | 226.6M |
| Shares outstanding | 37.4M | 37.0M | 30.6M | 30.3M | 29.5M | 29.3M | 29.2M | 29.1M | 27.7M | 27.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 12.6M | -206.0K | 257.0K | -17.4M | -22.6M | 16.5M | -17.0M | 16.0M | 19.8M | 29.8M |
| Capital spending | -6.34M | -13.4M | -18.4M | -29.9M | -26.2M | -19.3M | -12.2M | -44.7M | -33.6M | -23.0M |
| Free cash flow | 6.23M | -13.6M | -18.1M | -52.5M | -48.8M | -2.79M | -29.3M | -28.7M | -13.8M | 6.83M |
| Cash from investing | -1.63M | -6.42M | -18.4M | -4.81M | 80.0M | -12.3M | -23.9M | -96.8M | -35.6M | -25.4M |
| Cash from financing | -1.11M | 6.42M | 7.51M | 39.7M | -57.0M | -3.42M | 40.0M | 79.0M | 13.3M | -8.80M |
| Dividends paid | -3.08M | -274.0K | -212.0K | -700.0K | ||||||
| Share buybacks | -1.94M | -152.0K | -789.0K | -405.0K | -212.0K | -700.0K | -1.48M | -434.0K | ||
| Change in cash | -197.0K | -197.0K | -10.6M | 17.4M | 348.0K | 742.0K | -912.0K | -1.75M | -2.52M | -4.38M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| DEFM14A | Nov 13, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Nov 5, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| PREM14A | Oct 30, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 29, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 28, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Sep 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 28, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 10-KT · Transition report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 8-K · Current report | Mar 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 16, 2026 | Management or board change | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 31, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 30, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 26, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 25, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 22, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 18, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2025 | Offer document | SEC |
| 10-K · Annual report | Aug 7, 2025 | Annual report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Jul 18, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 10, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Apr 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 3, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Feb 27, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 21, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jan 17, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jan 2, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jan 2, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 26, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 21, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 8, 2024 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Oct 31, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 29, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Oct 23, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 18, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 16, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Oct 10, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Oct 10, 2024 | Offer document | SEC |
| S-1 · Registration statement | Oct 10, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Oct 10, 2024 | Offer document | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 4, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 4, 2024 | Results | SEC |
| DEF 14A · Proxy statement | Sep 23, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 23, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 4/A · Change in ownership, amended | Sep 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 29, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 26, 2024 | Results | SEC |
| 10-K · Annual report | Aug 26, 2024 | Annual report | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2024 | Management or board change | SEC |
| NT 10-K · Late filing notice | Aug 12, 2024 | Explanation request | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 9, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 24, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Jul 19, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Jul 8, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 5, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 1, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 1, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jun 13, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 11, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 7, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 22, 2024 | Insider trade | SEC |
| 8-K · Current report | May 22, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | May 20, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 16, 2024 | Current report | SEC |
| 8-K · Current report | May 14, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | May 13, 2024 | Other filings | SEC |
| 8-K · Current report | May 8, 2024 | Material contract | SEC |
| 8-K · Current report | May 7, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 30, 2024 | Current report | SEC |
| 8-K · Current report | Apr 19, 2024 | Current report | SEC |
| NT 10-Q · Late filing notice | Apr 8, 2024 | Explanation request | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 8-K · Current report | Mar 26, 2024 | Current report | SEC |
| 8-K · Current report | Mar 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 20, 2024 | Results | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 29, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 16, 2024 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 10, 2024 | Insider trade | SEC |
| NT 10-Q · Late filing notice | Jan 10, 2024 | Explanation request | SEC |
| 8-K · Current report | Jan 5, 2024 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 20, 2023 | Current report | SEC |
| 8-K · Current report | Oct 31, 2023 | Current report | SEC |
| 8-K · Current report | Oct 18, 2023 | Current report | SEC |
This page holds 200 of 1,005 filings. Open Filings
Cap table
Built by 6ix from Lifecore Biomedical, Inc.’s releases · as of Oct 28, 2026
- Common shares
- 37,905,846
- Fully diluted
- 37,905,846
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 37,905,846 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 37,905,846 |
| Aug 5, 2026 | 37,477,386 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason M. Aryeh Other companies: Orchestra BioMed Holdings, Inc. (Director · Since at least Jan 26, 2023); Anebulo Pharmaceuticals, Inc. (Board Member · Since at least May 6, 2021); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Myrexis Inc (Director · Oct 19, 2011 – Jun 18, 2012 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past) | Director · Since at least Aug 15, 2024 |
| Craig Barbarosh Other companies: Evolent Health, Inc (Director · Since at least Dec 21, 2020); Sabra Health Care REIT, Inc. (Director · Since at least Nov 5, 2010); ModivCare Inc (Director · Dec 23, 2024 – Dec 23, 2024 · Past); Aratana Therapeutics Inc (Director · May 18, 2018 – Jul 18, 2019 · Past); Bazaarvoice Inc (Director · Sep 27, 2017 – Feb 1, 2018 · Past); Timber Pharmaceuticals Inc (Director · Jan 26, 2016 – Jul 21, 2016 · Past); Nextgen Healthcare Inc (Director · Sep 17, 2009 – Nov 9, 2023 · Past) | Director · Oct 15, 2019 – Jul 8, 2024 · Past |
| Catherine Angell Sohn Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Altimmune, Inc. (Director · Since at least Mar 23, 2023); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Palisade Bio, Inc. (Director · Jan 13, 2014 – Jul 1, 2015 · Past); Jazz Pharmaceuticals plc (Director · Jul 27, 2012 – Aug 11, 2023 · Past) | Director · Nov 13, 2012 – Jun 4, 2022 · Past |
| Joshua Schechter Other companies: Barnwell Industries, Inc. (Director · Since at least Nov 28, 2025); Pursuit Attractions and Hospitality, Inc. (Director · Since at least Apr 11, 2015); Bed Bath & Beyond, Inc. (Director · May 29, 2019 – Jan 20, 2023 · Past); Genesco Inc. (Director · Apr 24, 2018 – Jun 27, 2018 · Past); Support.com Inc (Director · Jun 28, 2016 – Sep 14, 2021 · Past); The Pantry Inc (Director · Mar 13, 2014 – Mar 16, 2015 · Past) | Director · Since at least Oct 14, 2020 |
| Christopher S Kiper Other companies: NN, Inc. (Director · Since at least Jan 16, 2026); Clear Channel Outdoor Holdings, Inc. (Director · Since at least Jan 31, 2024); Momentive Global Inc (Director · Mar 1, 2022 – May 31, 2023 · Past); CIBER Inc (Director · Feb 3, 2017 – Feb 3, 2017 · Past); L.B. Foster Company (Director · Sep 14, 2016 – Jun 30, 2017 · Past) | Director · Since at least Jan 9, 2023 |
| Nelson Obus Other companies: Williams Industrial Services Group Inc (Director · Jun 27, 2016 – Feb 2, 2023 · Past); Jason Industries Inc (Director · Jul 30, 2015 – Jul 1, 2019 · Past); Breeze-Eastern Corp (Director · Feb 20, 2014 – Jan 4, 2016 · Past); Gilman Ciocia Inc (Director · Oct 3, 2008 – Oct 31, 2011 · Past); Layne Christensen Company (Director · Jan 1, 2006 – Jun 14, 2018 · Past) | Director · Since at least Oct 12, 2018 |
| Andrew Kenneth William Powell Other companies: ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Jun 10, 2022 · Past); Synthorx Inc (Director · Dec 19, 2018 – Jan 23, 2020 · Past); Aclaris Therapeutics, Inc. (Director · May 16, 2018 – Jun 1, 2024 · Past) | Director · Oct 12, 2018 – Jun 4, 2022 · Past |
| Jeffrey L. Edwards Other companies: Bio-Rad Laboratories, Inc. (Director · Since at least Apr 25, 2017); Kyntra Bio, Inc. (Director · Since at least Oct 28, 2015); Clearside Biomedical Inc (Director · Sep 26, 2018 – Jun 20, 2024 · Past) | Director · Oct 14, 2020 – Jul 8, 2024 · Past |
| Matthew E. Korenberg Other companies: Palvella Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 13, 2024); AIxCrypto Holdings, Inc. (Director · May 22, 2020 – Jul 11, 2022 · Past); Ligand Pharmaceuticals Incorporated (President & COO · Aug 6, 2015 – Sep 20, 2024 · Past) | Director · Since at least Aug 15, 2024 |
| Raymond T White Other companies: NN, Inc. (Director · Since at least Jan 16, 2026); Clear Channel Outdoor Holdings, Inc. (Director · Since at least Jan 31, 2024); Momentive Global Inc (Director · Mar 1, 2022 – May 31, 2023 · Past) | Director · Since at least Jan 9, 2023 |
All 47 people
| Person | Seat |
|---|---|
| Richard Dean Hollis Other companies: The Hain Celestial Group, Inc. (Director · Sep 27, 2017 – Nov 17, 2022 · Past); Diamond Foods Inc (Director · May 29, 2012 – Feb 29, 2016 · Past); Boulder Brands Inc (Director · Jul 5, 2011 – Jan 15, 2016 · Past) | Director · Jul 30, 2009 – Oct 14, 2015 · Past |
| Steven D Goldby Other companies: Accelrys Inc (Director · Jul 1, 2010 – Aug 3, 2011 · Past); Sunesis Pharmaceuticals Inc (Director · Jun 19, 2006 – Jun 5, 2008 · Past); Symyx Technologies Inc (Director · Feb 15, 2006 – Jul 1, 2010 · Past) | Director · Dec 11, 2008 – May 23, 2019 · Past |
| Tonia L Pankopf Other companies: WisdomTree, Inc. (Director · Since at least Jun 22, 2023); 180 Degree Capital Corp (Director · Aug 10, 2020 – Dec 31, 2021 · Past); Oxford Square Capital Corp. (Director · Jun 13, 2008 – Jun 13, 2008 · Past) | Director · Nov 13, 2012 – Jun 4, 2022 · Past |
| Albert D Bolles Other companies: Arcadia Biosciences, Inc. (Director · May 12, 2018 – Aug 19, 2024 · Past); ConAgra Brands, Inc. (EVP & Chief Tech & Op Officer · Mar 14, 2014 – Jul 17, 2015 · Past) | Chief Executive Officer · May 8, 2014 – May 23, 2022 · Past |
| Fred Frank Other companies: PDL BioPharma Inc (Director · Mar 11, 2009 – Jun 5, 2012 · Past); Pharmaceutical Product Development Inc (Director · Jan 3, 2006 – Dec 5, 2011 · Past) | Director · Jun 15, 2006 – Oct 14, 2020 · Past |
| Montgomery Molly Other companies: Tigo Energy, Inc. (Director · Aug 5, 2021 – Aug 10, 2021 · Past); Reservoir Media, Inc.. (Director · Dec 10, 2020 – Dec 15, 2020 · Past) | Chief Executive Officer · Jun 22, 2009 – Jun 6, 2019 · Past |
| Patrick D Walsh Other companies: ANI Pharmaceuticals, Inc. (Director · Since at least May 17, 2018); Avid Bioservices Inc (Director · Oct 20, 2017 – Dec 14, 2020 · Past) | Director · Oct 14, 2020 – Jun 4, 2021 · Past |
| Charles Macaluso Other companies: Williams Industrial Services Group Inc (Director · Feb 4, 2021 – Feb 4, 2021 · Past) | Director · Oct 15, 2020 – Oct 15, 2020 · Past |
| Deborah D Carosella Other companies: Arcadia Biosciences, Inc. (Director · Feb 22, 2021 – Aug 19, 2024 · Past) | Director · Mar 14, 2017 – Jun 4, 2022 · Past |
| Nathaniel Calloway Other companies: Anebulo Pharmaceuticals, Inc. (Director · Oct 28, 2022 – Apr 4, 2025 · Past) | Director · Jan 9, 2023 – Jul 8, 2024 · Past |
| Ryan D. Lake Other companies: Recro Pharma Inc (Chief Financial Officer · Jan 2, 2018 – Apr 8, 2024 · Past) | Chief Financial Officer · Since at least Sep 3, 2024 |
| Brian F McLaughlin | Chief Financial Officer · Oct 16, 2019 – Oct 19, 2020 · Past |
| Damian A Hajduk | Chief Scientific Officer · May 26, 2010 – May 24, 2013 · Past |
| David D Taft | Chief Operating Officer · Mar 27, 2006 – May 26, 2010 · Past |
| Dawn Kimball | Chief People Officer · Oct 16, 2019 – Mar 12, 2021 · Past |
| Dennis J Allingham | Executive Vice President · May 26, 2010 – May 30, 2013 · Past |
| Gary T Steele | Director · Jan 17, 2006 – May 30, 2018 · Past |
| Gregory S Skinner | Chief Financial Officer · Jun 15, 2006 – Jan 16, 2020 · Past |
| Humberto Calheiros Antunes | Director · Since at least Aug 15, 2024 |
| Jackie Klecker | Executive Vice President, Quality and Development Services · Since at least Apr 22, 2025 |
| James G Hall | Chief Executive Officer, Director · Apr 14, 2021 – Jun 1, 2023 · Past |
| John D Morberg | Chief Financial Officer · Jan 18, 2021 – Jan 18, 2024 · Past |
| Lovas Katrina Houde | Director · Since at least Aug 5, 2019 |
| Mark DaFonseca | Chief Commercial Officer · Since at least Oct 28, 2025 |
| Nicholas Tompkins | Director · May 26, 2016 – Oct 20, 2016 · Past |
| Parker K Javid | Vice President · Jul 25, 2018 – Oct 17, 2019 · Past |
| Paul Harold Johnson | Director · Since at least Aug 15, 2024 |
| Paul Josephs | Chief Executive Officer · Since at least May 20, 2024 |
| Raymond H Diradoorian | Director · Jan 20, 2022 – Jul 8, 2024 · Past |
| Robert Tobin | Director · Jun 15, 2006 – Oct 16, 2019 · Past |
| Ronald Lane Midyett | Chief Operations Officer · Jan 7, 2008 – May 23, 2018 · Past |
| Stephen E Halprin | Director · May 16, 2012 – Sep 12, 2014 · Past |
| Steven P Bitler | Vice President, Technology · Mar 31, 2006 – May 23, 2018 · Past |
| Thomas D Salus | Chief Legal & Administration · Since at least Apr 14, 2025 |
| Thomas Guldager | Sr. Vice President, Operations · Since at least Jan 2, 2025 |
| Timothy P Burgess | Senior VP of Supply Chain · Jul 25, 2019 – Jul 27, 2021 · Past |
| Tom Salus | Chief Legal and Administration Officer · Since at least Apr 14, 2025 |
Log in to ask 6ix AI your own questions about Lifecore Biomedical, Inc.